114 related articles for article (PubMed ID: 18597651)
1. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.
Lévesque E; Benoit-Biancamano MO; Delage R; Couture F; Guillemette C
Pharmacogenomics; 2008 Jul; 9(7):869-79. PubMed ID: 18597651
[TBL] [Abstract][Full Text] [Related]
2. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
[TBL] [Abstract][Full Text] [Related]
4. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
5. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
[TBL] [Abstract][Full Text] [Related]
6. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
[TBL] [Abstract][Full Text] [Related]
7. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
8. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
Xie XC; Li J; Wang HY; Li HL; Liu J; Fu Q; Huang JW; Zhu C; Zhong GP; Wang XD; Sun PP; Huang M; Wang CX; Li JL
Acta Pharmacol Sin; 2015 May; 36(5):644-50. PubMed ID: 25864649
[TBL] [Abstract][Full Text] [Related]
9. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
[TBL] [Abstract][Full Text] [Related]
10. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.
Guo D; Pang LF; Han Y; Yang H; Wang G; Tan ZR; Zhang W; Zhou HH
Eur J Clin Pharmacol; 2013 Apr; 69(4):843-9. PubMed ID: 23052409
[TBL] [Abstract][Full Text] [Related]
12. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
[TBL] [Abstract][Full Text] [Related]
13. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
Naesens M; Kuypers DR; Verbeke K; Vanrenterghem Y
Transplantation; 2006 Oct; 82(8):1074-84. PubMed ID: 17060857
[TBL] [Abstract][Full Text] [Related]
15. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.
Dostalek M; Court MH; Hazarika S; Akhlaghi F
Drug Metab Dispos; 2011 Mar; 39(3):448-55. PubMed ID: 21123165
[TBL] [Abstract][Full Text] [Related]
17. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Inoue K; Miura M; Satoh S; Kagaya H; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2007 Jun; 29(3):299-304. PubMed ID: 17529886
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
Božina N; Lalić Z; Nađ-Škegro S; Borić-Bilušić A; Božina T; Kaštelan Ž; Trkulja V
Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
[TBL] [Abstract][Full Text] [Related]
20. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
